Clinical trial
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and…
NCT00337389 · Mast Therapeutics, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00337389 |
|---|---|
| Title | Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. |
| Official title | A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma |
| Lead sponsor | Mast Therapeutics, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer |
| Intervention type | Drug |
| Interventions | 5- Fluorouracil (5-FU), bevacizumab (Avastin), Leucovorin, CoFactor (ANX-510) |
| Enrollment | 1,200 |
| Start date | May 1, 2006 |
| First posted | Jun 16, 2006 |
| Last update posted | Nov 19, 2007 |
| Countries | Serbia and Montenegro, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: